secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001104659-26-032116
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte announces $20M registered direct offering of 25M shares at $0.80/share
-------------------------------------------------------------------------------

- Gross proceeds of $20M from 25M shares at $0.80; net proceeds ~$18.4M after fees.
- Offering led by a new life science dedicated investor and a long-only mutual fund.
- Net proceeds to fund Symvess commercialization, hemodialysis Phase 3 read-out, and pipeline.
- Expected to close March 20, 2026, subject to customary closing conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000110465926032116/0001104659-26-032116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000110465926032116/tm269106d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-032116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer